Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast and Desloratadine as Adjuvant Therapy for Rheumatoid Arthritis
NCT07566351Phase 2Recruiting
- Sponsor
- Horus Pharma
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roflumilast, desloratadine in rheumatoid arthritis (RA), sponsored by Horus Pharma. Started Apr 2026; status: recruiting.
02
Drugs
roflumilastdesloratadine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07566351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07566351.